Relapsed refractory multiple myeloma

Multiple myeloma (A cancer arising from plasma cells)

Multiple myeloma (A cancer arising from plasma cells)

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer

CAR-T therapy and impact to cancer patient outcomes and experience of treatment

Haemato-oncological Cancers

Selpercatinib benefit, with or without pembro, in first-line advanced RET fusion-positive NSCLC

Datopotamab deruxtecan extends PFS vs chemo for HR+/HER2- breast cancer

Enfortumab vedotin plus pembrolizumab improves overall survival for advanced bladder cancer

Nivolumab plus gemcitabine-cisplatin shows benefit for locally advanced mUC

Durvalumab addition to chemo shows endometrial cancer benefit

Adagrasib pembrolizumab combo shows promise for KRASG12C-positive NSCLC